Diabetogen

The vice-president of Robarts Research Institute is attempting to put together a financing structure for a biotechnology company, Diabetogen, being spun off by the Institute. He must assess the worth of the company, how the equity should be divided among its stakeholders, and how much of the company must be given up to first-round investors.